Since the European Commission launched its small business act for Europe in 2008, several discussions have been going on concerning the thorny issue of late payment. Up to 80 per cent of the medical sector is composed of SMEs and late payment nowadays is a cause for disinvestment in research and development, and even bankruptcy. What does that mean for patients? It means that the know-how and expertise that comprise the core competence of each company is put in jeopardy even though there is demand for their services. This means that the products and services that those companies intend to develop for better treatment services will never be available because they cannot fund their business.
Read our news piece here.